People: Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

3.65AUD
27 Mar 2015
Change (% chg)

$0.07 (+1.96%)
Prev Close
$3.58
Open
$3.62
Day's High
$3.77
Day's Low
$3.58
Volume
1,370,377
Avg. Vol
462,352
52-wk High
$5.88
52-wk Low
$3.50

Search Stocks

Summary

Name Age Since Current Position

Brian Jamieson

2007 Independent Non-Executive Chairman of the Board

Silviu Itescu

2014 Chief Executive Officer, Executive Director

Paul Hodgkinson

2014 Group Chief Financial Officer

Charlie Harrison

2014 Company Secretary

William Burns

2014 Non-Executive Independent Director

Donal O'Dwyer

60 2014 Non-Executive Independent Director

Eric Rose

63 2014 Non-Executive Independent Director

Michael Spooner

2014 Non-Executive Independent Director

Ben-Zion Weiner

70 2014 Non-Executive Independent Director

Julie Meldrum

Global Head - Corporate Communications

Biographies

Name Description

Brian Jamieson

Mr. Brian Jamieson, FCA, has been Independent Non-Executive Chairman of the Board of Mesoblast Ltd., since November 22, 2007. Brian Jamieson was Chief Executive of Minter Ellison Melbourne and a partner of the Minter Ellison Revenue Group from 2002 to 2005, when he retired as Chief Executive. Prior to joining Minter Ellison, he was Chief Executive at KPMG Australia from 1998 to 2000, Managing Partner of KPMG Melbourne and Southern Regions from 1993 to 1998 and Chairman of KPMG Melbourne from 2001 to 2002. Mr Jamieson was also a KPMG Board Member in Australia and a member of the United States Management Committee. He has over 30 years of experience providing advice and audit services to a diverse range of public and large private companies and is a fellow of the Institute of Chartered Accountants in Australia. He has been Chairman, Sigma Pharmaceuticals Limited (since 2005); Non-executive Director, Tatts Group Limited (since 2005); Non-executive Director, OZ Minerals Limited (since 2004); and Non-executive Director, Tigers Realm Coal Limited (since 2011). He is Member of the Audit & Risk Committee and Member of the Remuneration and Nomination Committee.

Silviu Itescu

Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACR, is Chief Executive Officer, Executive Director of Mesoblast Ltd., Prior to founding Mesoblast in 2004, Professor Silviu Itescu established an outstanding international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He is an active faculty member of Melbourne and Monash universities in Australia and was previously a faculty member of Columbia University in New York. Under his leadership, Mesoblast has become the world’s largest regenerative medicine company, and received the 2011 Deals of Distinction™ Award from The Licensing Executives Society (United States and Canada) Inc. for its alliance with Cephalon, Inc., later acquired by Teva Pharmaceutical Industries Ltd. In 2011, Professor Itescu was named BioSpectrum Asia Person of the Year. In 2013 he received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership and ingenuity in translational science and clinical medicine in relation to adult stem cell therapy. Professor Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of a number of publicly-listed life sciences companies.

Paul Hodgkinson

Mr. Paul Hodgkinson has been appointed as Group Chief Financial Officer of Mesoblast Limited., with effect from 25 August 2014. Mr Hodgkinson has broad and high-level international pharmaceutical experience in all aspects of finance, strategic planning, business development and licensing, manufacturing and supply chain, and procurement. From 2011 to 2014, Mr Hodgkinson was Chief Financial Officer and had full financial responsibility for the Novartis ANZ Group of companies and divisions comprising Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, Consumer and Animal Health. Previously, he held a number of leadership roles with AstraZeneca in the United Kingdom, including Global Licensing Finance Director, before being appointed Chief Financial Officer for AstraZeneca Australia from 2006 to 2011.

Charlie Harrison

Mr. Charlie Harrison has been appointed as Company Secretary of Mesoblast Limited., with effect from 1 September 2014. Mr Harrison joined Mesoblast as legal counsel in 2013. Previously he was a senior associate at the international law firm Allens, working in their Hong Kong and Melbourne offices for nine years as a corporate lawyer.

William Burns

Mr. William Burns has been appointed as Non-Executive Independent Director of Mesoblast Ltd., with effect from March 6, 2014. He has spent his entire management career in two companies, the Beecham Group and F. Hoffmann-La Roche Ltd. He was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of F. Hoffmann-La Roche until he retired in 2014. His responsibilities spanned from research to commercialization. Mr Burns has also served on the Board of Directors of Genentech, and as a Director of Chugai Pharmaceutical Co. Additional roles have included as Chairman of biologic company Okairos, acquired in 2013 by GlaxoSmithKline, and Crucell, acquired in October 2011 by Johnson & Johnson. He chaired the Swiss Research Trade Association for several years and represented the company on the European and International Trade Associations Management Boards. He also supports the Wellcome Trust New Technologies group and is a member of the Oncology Advisory Board of the Universities of Cologne/Bonn.

Donal O'Dwyer

Mr. Donal P. O'Dwyer, BE, MBA, is Non-Executive Independent Director of Mesoblast Ltd. Donal O’Dwyer has over 25 years of experience as a senior executive in the global cardiovascular and medical devices industries. From 1996 to 2003, he worked for Cordis Cardiology, the cardiology division of Johnson & Johnson’s Cordis Corporation, initially as its President (Europe) and as its worldwide President from 2000. In his role, Mr O’Dwyer led Cordis through the launch of the revolutionary Cypher drug eluting coronary stent technology, and saw the company take over number one market share of coronary stents worldwide. Prior to joining Cordis, he worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to President of the Cardiovascular Group, Europe (now Edwards Lifesciences). Mr O’Dwyer is a qualified civil engineer and has an MBA. He has been Non-executive Director, Cochlear Limited (since 2005); Non-executive Director, Atcor Medical Holdings Limited (since 2004); and Non-executive Director, Fisher & Paykel Healthcare (since 2013). He was Non-executive Director, Sunshine Heart (from 2004 to 2013). He is Chairman of the Remuneration and Nomination Committee and Member of the Audit & Risk Committee.

Eric Rose

Dr. Eric A. Rose, M.D., has been Non-Executive Independent Director of Mesoblast Ltd., Eric Rose is a world leader in cardiovascular medicine. He is currently Chairman and CEO of SIGA Technologies and Executive Vice President, Life Sciences, at MacAndrews & Forbes, Inc., the holding company of Ronald O. Perelman. From 2008 through 2012, Dr Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine, which has an extensive portfolio of research focused on evaluation of complex medical technologies in cardiovascular disease, cancer, diabetes mellitus, and neurologic disease. From 1994 through 2007, Dr Rose served as Chairman of the Department of Surgery and Surgeonin- Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 to 1992, he led the Columbia Presbyterian heart transplantation program, during which time it became the most active program in the United States. Dr Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984. He has investigated many alternatives to heart transplantation, including cross species transplantation and man-made heart pumps and is also Chairman of the Board of Circulite, Inc., a developer of advanced left ventricular assist devices. Dr Rose has authored or co-authored more than 300 scientific publications and has received more than $25 million in National Institutes of Health support for his research. He has been Director of SIGA Technologies (since 2001) and was Director of ABIOMED (2007 to 2012).

Michael Spooner

Mr. Michael R. Spooner, Bcom, ACA, MAICD, is Non-Executive Independent Director of Mesoblast Ltd., Michael Spooner is a well-known and respected business leader. He has an extensive network of relationships with investment firms and business communities across the globe, having spent the majority of the past 25 years living and working internationally. Mr Spooner consults for a number of listed and unlisted companies based in Australia and the United States. Most recently, he was a non-executive Director of Hawaii Biotech Inc., a specialty developer of vaccines from 2010 to 2011. In 2009, Mr Spooner was appointed Chairman of BiVACOR, a total artificial heart company. He was also a non-executive Director of Peplin Inc., a dermatology-focused skin cancer company from 2004 until the company was sold in 2009 for over $300 million. Previously, Mr Spooner was the Chairman of Mesoblast Limited from its initial listing in 2004 until 2007 and Managing Director & CEO of Ventracor Limited where he led the transformation of a small Australialisted life sciences company into the second highest performing stock on the S&P/ASX 200 Index. He was also a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong for several years. He was Non-executive director of Advanced Surgical Design (from 2010 to 2011). He is Chairman of the Audit & Risk Committee and Member of the Remuneration and Nomination Committee.

Ben-Zion Weiner

Dr. Ben-Zion Weiner, ph.D., has been Non-Executive Independent Director of Mesoblast Ltd since May 9, 2012. Ben-Zion Weiner was head of global research and development at Teva Pharmaceutical Industries Ltd for over three decades, including as Chief R&D Officer and a member of the Teva Executive Committee. He directly oversaw all pharmaceutical R&D and innovative branded product pipeline development. Dr Weiner has been responsible for the development of hundreds of generic products for the United States, European and other markets. In parallel, he has been responsible for the development and regulatory approval of Teva’s innovative product portfolio. Dr Weiner has twice been the recipient of the Rothschild prize for innovation, including for the commercialization of Copaxone in the treatment of multiple sclerosis. He retired from Teva at the end of 2012. Dr Weiner is no longer affiliated with Teva and continues to serve on the Mesoblast Board as an independent nonexecutive Director. He was Director of Gefen Biomed Investments Ltd (2010 to 2013) and Board Member of XTL Biopharmaceuticals Limited (2012 to 2013).

Julie Meldrum

Basic Compensation

Name Fiscal Year Total

Brian Jamieson

343,322

Silviu Itescu

1,817,780

Paul Hodgkinson

--

Charlie Harrison

--

William Burns

44,145

Donal O'Dwyer

174,436

Eric Rose

142,167

Michael Spooner

177,167

Ben-Zion Weiner

134,667

Julie Meldrum

--
As Of  29 Jun 2014
Search Stocks